
Cumberland Pharmaceuticals CPIX
$ 3.06
0.66%
Quarterly report 2025-Q3
added 11-07-2025
Cumberland Pharmaceuticals Deferred Revenue 2011-2026 | CPIX
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Cumberland Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 207 K | 220 K | 615 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 615 K | 207 K | 347 K |
Deferred Revenue of other stocks in the Drug manufacturers industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aurora Cannabis
ACB
|
27 M | $ 3.45 | 0.58 % | $ 86.3 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
27.8 K | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
85.4 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
49 K | - | 7.5 % | $ 6.35 M | ||
|
Assertio Holdings
ASRT
|
200 K | $ 11.77 | 1.99 % | $ 836 M | ||
|
DURECT Corporation
DRRX
|
545 K | - | - | $ 50.1 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
114 K | - | - | $ 2.06 B | ||
|
Eagle Pharmaceuticals
EGRX
|
6 M | - | -39.89 % | $ 27.7 M | ||
|
Evolus
EOLS
|
11.5 M | $ 5.04 | 0.6 % | $ 325 M | ||
|
HEXO Corp.
HEXO
|
8.21 M | - | 2.45 % | $ 38.1 M | ||
|
Catalent
CTLT
|
250 M | - | - | $ 11.5 B | ||
|
Athenex
ATNX
|
2.82 M | - | -23.39 % | $ 1.76 M | ||
|
Endo International plc
ENDP
|
600 K | - | - | $ 28.9 M | ||
|
Harrow Health
HROW
|
788 K | $ 34.91 | 2.38 % | $ 1.28 B | ||
|
Emergent BioSolutions
EBS
|
27.2 M | $ 8.33 | 3.22 % | $ 426 M | ||
|
China Pharma Holdings
CPHI
|
162 K | $ 0.62 | 2.94 % | $ 10.8 M | ||
|
Pacira BioSciences
PCRX
|
102 K | $ 22.69 | -2.45 % | $ 1.05 B | ||
|
ProPhase Labs
PRPH
|
2.5 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
1 M | - | - | $ 1.42 B | ||
|
Perrigo Company plc
PRGO
|
122 M | $ 9.72 | 4.4 % | $ 1.35 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
641 K | $ 2.4 | -2.24 % | $ 2.98 M | ||
|
Rockwell Medical
RMTI
|
46 K | $ 0.96 | 6.61 % | $ 22.4 M | ||
|
OptiNose
OPTN
|
160 K | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
235 K | $ 0.9 | 4.68 % | $ 44.9 M | ||
|
Recro Pharma
REPH
|
543 K | - | -4.76 % | $ 65.3 M | ||
|
TherapeuticsMD
TXMD
|
523 K | $ 2.17 | - | $ 22.7 M | ||
|
Solid Biosciences
SLDB
|
10.4 M | $ 7.48 | 2.33 % | $ 305 M | ||
|
Veru
VERU
|
400 K | $ 2.37 | -0.84 % | $ 320 M | ||
|
Tilray
TLRY
|
23.7 M | $ 6.9 | 0.15 % | $ 4.26 B | ||
|
cbdMD
YCBD
|
503 K | $ 0.72 | 1.41 % | $ 3.11 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
172 K | - | - | $ 55.5 M | ||
|
Zomedica Corp.
ZOM
|
368 K | - | -0.21 % | $ 98 M |